STOCKHOLM, March 21, 2016 /PRNewswire/ --
Premune and Innovet Italia announced today that they have expanded their collaboration by signing an exclusive licensing agreement for six additional products, targeting three key areas in companion animal well-being. The extended product range now includes Retopix® Spray, Retopix® Fluid, and Retopix® Oto (skin care), Normalia® (support of gut function) and Oculvet® Wipes and Oculvet® Drops (eye care).
The companies initiated a collaboration in August 2015 with the exclusive licensing agreement for Redonyl® Ultra, a nutritional supplement for support of normal skin function in cats and dogs based on PEA-um® (ultramicronized palmitoylethanolamide). Palmitoylethanolamide is a naturally occurring compound produced on demand by the body in response to inflammation and pain. Retopix®, Normalia® and Oculvet® all contain either PEA-um® or Adelmidrol, an analogue of PEA formulated specifically for topical administration.
The expanded collaboration gives Premune exclusive marketing rights for key European countries, with the option to expand to other geographies including North America. This brings the current Premune portfolio to seven products, all of which will be launched during 2016.
Premune has already begun its launch efforts for the portfolio in Europe. As a part of its marketing and sales activities, the company will introduce the dermatology line, together with Innovet, at the upcoming 8th World Congress of Veterinary Dermatology in Bordeaux, France, 31 May - 4 June 2016.
Premune is a commercial stage animal health company focused on novel therapeutics and supplements for some of the most common conditions affecting companion animals. The company is continuously seeking to expand its therapeutic portfolio through a combination of strategic in-licensing, in-house research and development projects and collaborative development initiatives. Premune´s goal is to improve the quality of life for companion animals worldwide with science-backed, differentiated innovations. For more information, visit http://www.premune.com.
Innovet Italia is an innovation animal health company, founded in 1996. Its main goal is to bring scientific innovation in niche fields of the veterinary market. The philosophy, which drives Innovet's development, is to follow where Nature leads, studying and miming natural protection body responses rather than "artificially" fighting the symptoms of diseases. Based on such a strategic idea, Innovet's research team discovered and patented a family of bioactive lipid amides (i.e., aliamides, whose parent compound is palmitoylethanolamide, PEA) able to naturally restore the physiological balance of the hyper-reactive tissues. PEA, its micronized and ultramcronized forms and various other congeners, are the main components of Innovet's innovative products. Innovet's commercial effort is mainly focused on small animals health field in various market segments, the main being dermatology, orthopedics, and algology. For more information: http://www.innovet.it
For more information, please contact:
Omid Ekhlasi, PR & Investor Relations